Åsa Hagner Mcwhirter

Principal Scientist • Cytiva

Åsa has been with Cytiva based in Uppsala, Sweden since 2003 and is a Downstream and analytics SME, with a broad and deep understanding of viral vector processing. Due to her long experience and from customer interactions she has gained insights into common challenges and pitfalls in the area of viral vectors and vaccines as well as general protein purification and analysis. She has also worked with proteomics and fluorescent-based protein analysis technologies.

Åsa holds a PhD in Medical Biochemistry from Uppsala University in 1999 based on research around biosynthesis of proteoglycans. The studies involved polysaccharide structure analysis, enzyme purification & cloning as well as characterizing an enzyme reaction

Also Speaking

John Campbell

Director, Tissues, Cells & Advanced Therapeutics • Scottish National Blood & Transplant Service

Stefano Baila

Managing Director • Eurofins

Kevin Ramdas

Director, Clinical Operations • Longeveron

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.